LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma


Last updated date
Study Location
University of California Los Angeles
Los Angeles, California, 90024, United States


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

MelanomaStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Fayetteville, Arkansas
  6. Rogers, Arkansas
  7. Orange County, California
  8. Orange, California
  9. Orange, California
  10. Aurora, Colorado
  11. Boulder, Colorado
  12. Colorado Springs, Colorado
  13. Denver, Colorado
  14. Lakewood, Colorado
  15. Parker, Colorado
  16. Pueblo, Colorado
  17. Chicago, Illinois
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Goshen, Indiana
  22. Goshen, Indiana
  23. Grand Rapids, Michigan
  24. Grand Rapids, Michigan
  25. Grand Rapids, Michigan
  26. Jackson, Mississippi
  27. Jackson, Mississippi
  28. Hackensack, New Jersey
  29. Rochester, New York
  30. Dallas, Texas
  31. Burlington, Vermont
  32. Burlington, Vermont
  33. Burlington, Vermont
  34. Alexandria, Virginia
  35. Arlington, Virginia
  36. Fairfax, Virginia
  37. Fairfax, Virginia
  38. Fairfax, Virginia
  39. Falls Church, Virginia
  40. Gainesville, Virginia
  41. Leesburg, Virginia
  42. Woodbridge, Virginia
  43. Wenatchee, Washington
  44. Caba, Buenos Aires
  45. Buenos Aires, Ciudad Autónoma DE Buenosaires
  46. Buenos Aires, Ciudad Autónoma DE Buenosaires
  47. Buenos Aires, Ciudad Autónoma DE Buenosaires
  48. Buenos Aires, Ciudad Autónoma DE Buenosaires
  49. Buenos Aires, Ciudad Autónoma DE Buenosaires
  50. Buenos Aires, Ciudad Autónoma DE Buenosaires
  51. Gateshead, New South Wales
  52. Southport, Queensland
  53. Southport, Queensland
  54. Southport, Queensland
  55. Woolloongabba, Queensland
  56. Prahran, Victoria
  57. Nedlands, Western Australia
  58. Recife, Pernambuco
  59. Ijuí, RIO Grande DO SUL
  60. Porto Alegre, RIO Grande DO SUL
  61. Barretos, SAO Paulo
  62. Natal,
  63. Rio de Janeiro,
  64. Sao Paulo,
  65. Calgary, Alberta
  66. Toronto, Ontario
  67. Toronto, Ontario
  68. Toronto, Ontario
  69. Montreal, Quebec
  70. Montreal, Quebec
  71. Montreal, Quebec
  72. Montreal, Quebec
  73. Québec, Quebec
  74. Bogotá, Distrito Capital DE Bogotá
  75. Bogotá, Pbx (57-1)
  76. Brno, Jihomoravský KRAJ
  77. Praha 10, Praha, Hlavní Mesto
  78. Praha 2, Praha, Hlavní Mesto
  79. Brno,
  80. Olomouc,
  81. Ostrava Poruba,
  82. Praha,
  83. Nice, Alpes-maritimes
  84. Bordeaux, Gironde
  85. Grenoble, Isère
  86. Reims, Marne
  87. Lille, Nord
  88. Lyon, Rhone
  89. Lyon, Rhône
  90. Le Mans, Sarthe
  91. Villejuif, Val-de-marne
  92. Boulogne-Billancourt,
  93. Lille,
  94. Lyon,
  95. Nice,
  96. Paris,
  97. Paris,
  98. Paris,
  99. Paris,
  100. Pierre-bénite,
  101. Strasbourg,
  102. Templemars,
  103. Villejuif,
  104. Freiburg im Breisgau, Baden-württemberg
  105. Heidelberg, Baden-württemberg
  106. Mannheim, Baden-württemberg
  107. Tübingen, Baden-württemberg
  108. Ulm, Baden-württemberg
  109. München, Bayern
  110. Regensburg, Bayern
  111. Regensburg, Bayern
  112. Würzburg, Bayern
  113. Frankfurt, Hessen
  114. Kassel, Hessen
  115. Kassel, Hessen
  116. Buxtehude, Niedersachsen
  117. Buxtehude, Niedersachsen
  118. Bonn, Nordrhein-westfalen
  119. Minden, Nordrhein-westfalen
  120. Minden, Nordrhein-westfalen
  121. Mainz, Rheinland-pfalz
  122. Magdeburg, Sachsen-anhalt
  123. Dresden, Sachsen
  124. Leipzig, Sachsen
  125. Berlin, Schleswig-holstein
  126. Luebeck, Schleswig-holstein
  127. Lübeck, Schleswig-holstein
  128. Berlin,
  129. Bonn,
  130. Bonn,
  131. Dresden,
  132. Dresden,
  133. Erfurt,
  134. Erfurt,
  135. Essen,
  136. Freiburg,
  137. Gera,
  138. Gera,
  139. Gera,
  140. Hamburg,
  141. Hannover,
  142. Hannover,
  143. Hannover,
  144. Heidelberg,
  145. Homburg,
  146. Kiel,
  147. Lübeck,
  148. Magdeburg,
  149. Magdeburg,
  150. Mainz,
  151. Mannheim,
  152. Minden,
  153. Münster,
  154. Nürnberg,
  155. Regensburg,
  156. Tübingen,
  157. Ulm,
  158. Ulm,
  159. Athens, Attiki
  160. Athens,
  161. Athens,
  162. Piraeus,
  163. Budapest,
  164. Budapest,
  165. Debrecen,
  166. Szolnok,
  167. Ramat Gan, Tel-aviv
  168. Haifa,
  169. Jerusalem,
  170. Torrette Site, Ancona
  171. Napoli, Campania
  172. Roma, Lazio
  173. Roma, Lazio
  174. Lecco, Lombardia
  175. Milan, Lombardia
  176. Monza, Lombardia
  177. Rozzano, Lombardia
  178. Rozzano, Lombardia
  179. Candiolo, Torino
  180. Pisa, Toscana
  181. Terni, Umbria
  182. Padua, Veneto
  183. Bari,
  184. Bergamo,
  185. Bologna,
  186. Genoa,
  187. Milano,
  188. Napoli,
  189. Padova,
  190. Pavia,
  191. Ragusa,
  192. Siena,
  193. Torino,
  194. Fukuoka-shi, Fukuoka
  195. Matsumoto, Nagano
  196. Chuo-ku, Tokyo
  197. Niigata,
  198. Osaka, Ôsaka
  199. Gangnam-Gu, Seoul Teugbyeolsi
  200. Songpa-Gu, Seoul Teugbyeolsi
  201. Seoul,
  202. Seoul,
  203. Seoul,
  204. Seoul,
  205. Mexico,
  206. Mexico,
  207. Nijmegen, Gelderland
  208. Heerlen, Limburg
  209. Amsterdam, Noord Holland
  210. Breda, Noord-brabant
  211. Eindhoven, Noord-brabant
  212. Veldhoven, Noord-brabant
  213. Zwolle, Overijssel
  214. Enschede,
  215. Groningen,
  216. Leiden,
  217. Maastricht,
  218. Rotterdam,
  219. Rotterdam,
  220. Sittard-Geleen,
  221. Oslo,
  222. Oslo,
  223. Oslo,
  224. Warsaw, Mazowieckie
  225. Warszawa, Mazowieckie
  226. Warszawa,
  227. Lisbon, Lisboa
  228. Porto, Proto
  229. Almada,
  230. Lisboa,
  231. Lisboa,
  232. Lisboa,
  233. Porto,
  234. Moscow,
  235. St. Petersburg,
  236. Singapore,
  237. Singapore,
  238. Singapore,
  239. Bratislava,
  240. Bratislava,
  241. Bratislava,
  242. Poprad,
  243. Pretoria,
  244. Pretoria,
  245. Jerez De La Frontera, Andalucía
  246. Oviedo, Asturias
  247. Barcelona, Cataluña
  248. El Palmar, Murcia
  249. Pamplona, Navarra
  250. Pamplona, Navarra
  251. Alicante,
  252. Badalona,
  253. Barcelona,
  254. Barcelona,
  255. Barcelona,
  256. Barcelona,
  257. Donostia-san Sebastián,
  258. Dos Hermanas,
  259. Granada,
  260. La Coruna,
  261. Lleida,
  262. Lleida,
  263. Madrid,
  264. Madrid,
  265. Madrid,
  266. Madrid,
  267. Majadahonda,
  268. Malaga,
  269. Sevilla,
  270. Sevilla,
  271. Sevilla,
  272. Valencia,
  273. Göteborg,
  274. Lund,
  275. Solna,
  276. Uppsala,
  277. Zurich, Zürich (DE)
  278. Bern,
  279. Zürich,
  280. Zürich,
  281. Zürich,
  282. Bornova,
  283. Izmir,
  284. Izmir,
  285. Cambridge, Cambridgeshire
  286. Preston, Lancashire
  287. London, London, CITY OF
  288. Guildford, Surrey
  289. Bebington, Wirral
  290. Sheffield, York
  291. Broomfield,
  292. Leeds,
  293. London,
  294. Manchester,
  295. Oxford,
  296. Oxford,
18 Years+
MelanomaPfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
  1. New York, New York
18 Years+
MelanomaPhase I Oncovir Poly IC:LC and NY-ESO-1/gp100
  1. Tampa, Florida
18 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Official Title  ICMJE A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma
Brief Summary The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.
Detailed Description

This study consists of two parts: in Part I/Run-In, patients naïve to selective BRAF and MEK inhibitors will be treated with the LGX818/MEK162 combination until disease progression (as defined per RECIST v1.1). Based on the genetic analysis of a tumor biopsy obtained at that time, patients will enter Part II of the study for tailored combination treatment in one of four arms of LGX818/MEK162 + either BKM120, BGJ398, INC280 or LEE011 Patients with BRAF mutant melanoma treated by LGX818/MEK162 combination in other studies can be enrolled directly in Part II of CLGX818X2109 after relapse.

Dose-escalations in the combination arms for which no MTD has been established will be based on the recommendations of a Bayesian logistic regression model guided by an escalation with overdose control criterion

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Melanoma
Intervention  ICMJE
  • Drug: LGX818
    Combination of LGX818 and MEK162 (Part I)
  • Drug: MEK162
    Combination of LGX818 and MEK162 (Part I)
  • Drug: LEE011
    Combination of LGX818 + MEK162 + LEE011 (Part II)
  • Drug: BGJ398
    Combination of LGX818 + MEK162 + BGJ398 (Part II)
  • Drug: BKM120
    Combination of LGX818 + MEK162 + BKM120 (Part II)
  • Drug: INC280
    Combination of LGX818 + MEK162 + INC280 (Part II)
Study Arms  ICMJE
  • Experimental: LGX818 + MEK162
    • Drug: LGX818
    • Drug: MEK162
  • Experimental: LGX818 + MEK162 + LEE011
    Intervention: Drug: LEE011
  • Experimental: LGX818 + MEK162 + BGJ398
    Intervention: Drug: BGJ398
  • Experimental: LGX818 + MEK162 + BKM120
    Intervention: Drug: BKM120
  • Experimental: LGX818 + MEK162 + INC280
    Intervention: Drug: INC280
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: September 1, 2020)
Original Estimated Enrollment  ICMJE
 (submitted: June 5, 2014)
Estimated Study Completion Date  ICMJE January 31, 2022
Estimated Primary Completion Date January 17, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE


  • Age ? 18 years
  • Histologically confirmed diagnosis of unresectable stage III or metastatic melanoma (stage IIIC to IV per American Joint Committee on Cancer [AJCC])
  • Documented evidence of BRAF V600 mutation.
  • Newly obtained tumor biopsy at baseline, and patient agrees to a mandatory biopsy at the time of progression, if not medically contraindicated.
  • Evidence of measurable disease, as determined by RECIST v1.1.

INCLUSION CRITERIA for triple combinations:

Progressive disease following prior treatment with LGX818/MEK162 combination. PRINCIPAL EXCLUSION CRITERIA Symptomatic or untreated leptomeningeal disease.

  • Symptomatic brain metastases. Patients previously treated or untreated for brain metastases that are asymptomatic in the absence of corticosteroid therapy or on a stable dose of steroids for four weeks are allowed to enroll. Brain metastases must be stable at least 4 weeks with verification by imaging (e.g. brain MRI completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs.
  • Patients who have developed brain metastases during Part I of the study may continue to Part II upon discussion with Novartis Medical Monitor. The brain metastasis must be either asymptomatic or treated and stable for at least 4 weeks and on a stable or tapering dose of steroids for at least 2 weeks. Patients with brain metastasis are not eligible for the combination with LEE011.
  • Known acute or chronic pancreatitis.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);
  • Clinically significant cardiac disease including any of the following:
  • CHF requiring treatment (NYH grade ? 2),
  • LVEF < 50% as determined by MUGA scan or ECHO
  • History or presence of clinically significant ventricular arrhythmias or atrial fibrillation
  • Clinically significant resting bradycardia
  • Unstable angina pectoris ? 3 months prior to starting study drug
  • Acute Myocardial Infarction (AMI) ? 3 months prior to starting study drug,
  • QTcF > 480 msec. Patients with any of the following laboratory values at


  • Absolute neutrophil count (ANC) <1,500/mm3 [1.5 x 109/L]
  • Platelets < 100,000/mm3 [100 x 109/L]
  • Hemoglobin < 9.0 g/dL
  • Serum creatinine >1.5 x ULN or calculated or directly measured CrCl < 50% LLN (lower limit of normal)
  • Serum total bilirubin >1.5 x ULN
  • AST/SGOT or ALT/SGPT > 2.5 x ULN, or > 5 x ULN if liver metastases are present

Additional exclusion criteria for the triple combinations:


  • Patients with fasting glucose > 120 mg/dL or 6.7 mmol/L, and HbA1c > 8 %.
  • Patient has any of the following mood disorders as judged by the

Investigator or a Psychiatrist:

  • Patient has a score ? 12 on the PHQ-9 questionnaire
  • Patient has ? CTCAE grade 3 anxiety


  • History and/or current evidence of significant ectopic mineralization/ calcification with the exception of calcified lymph nodes and asymptomatic vascular calcification.
  • Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/ band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivits etc., confirmed by ophthalmologic examination


  • Patients with uncontrolled hypertension (please refer to WHO-ISHguidelines) are excluded from study.
  • QTcF >450 ms for males and >470 ms for females Congenital long QT syndrome or family history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ? 3 and magnesium levels below the clinically relevant lower limits at study entry
  • Current evidence of brain metastasis or brain metastasis detected by mandatory CT/MRI at screening
  • PT/INR or aPTT > 1.5xULN

Other protocol-defined inclusion/exclusion criteria may apply.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Canada,   Germany,   Italy,   Netherlands,   Spain,   Switzerland,   United Kingdom,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT02159066
Other Study ID Numbers  ICMJE CLGX818X2109
C4221013 ( Other Identifier: Alias Study Number )
2013-004552-38 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP